Evolving Paradigms in Pancreatic Cancer: References

Evolving Paradigms in Pancreatic Cancer: Frontline Treatment Regimens

Reference 7:Minimizing Adverse Events With Dose Modification in Pancreatic Cancer

References 8-10:Factors Determining Frontline Therapy Selection for Pancreatic Cancer

References 11-13:Second-Line Options Allow for Treatment Sequencing in Pancreatic Cancer

Reference 14:Earlier Use on Horizon for Novel Agents in Pancreatic Cancer

References 15-20:New Agents Under Exploration in Pancreatic Cancer

References

1. National Cancer Institute. SEER stat fact sheets: pancreas cancer. NCI website. http://seer.cancer.gov/statfacts/html/pancreas.html. Published April 2016. Accessed April 28, 2016.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol.1997;15(6):2403-2413.
3. Moore MJ, Goldstein D, HammJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol. 2007;25(15):1960-1966.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer.N Engl J Med. 2011;364:1817-1825.
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.N Engl J Med. 2013; 369:1691-1703.
6. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.J Natl Cancer Inst. 2015;107(2). doi: 10.1093/jnci/dju413.
7. Krishna K, Blazer MA, Wei L, et al. Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience. 2015 Gastrointestinal Cancers Symposium; January 15-17, 2015; San Francisco, CA. Abstract 366.
8. Braiteh FS, Patel M, Parisi M, et al. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P + G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma in a US community oncology setting.J Clin Oncol. 2016;34 (suppl 4S; abstract 433).
9. Chiorean EG, Whiting S, Binder G, et al. Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer.J Clin Oncol.2014;32(suppl 3;abstr 363).
10. Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P+GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC).J Clin Oncol. 2015;33 (suppl; abstr 6605).
11. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.Eur J Cancer. 2011;47(11):1676-1681.
12. Chen L-T, Von Hoff DD, Li C-P, et al. Expanded analyses of NAPOLI-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.J Clin Oncol. 2015;33 (suppl 3; abstr 234).
13. Goldstein D, Chiorean EG, Tabernero J, et al. Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).J Clin Oncol. 2016;34 (suppl 4S; abstract 333).
14. Peterson S, Loaiza-Bonilla A, Ben-Josef E, et al. Neoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOX.J Clin Oncol. 2016;34 (suppl 4S; abstr 328).
15. Hingorani SR, Harris WP, Hendifar AE, et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.J Clin Oncol. 2015;33 (suppl; abstr 4006).
16. Hidalgo M, Cooray P, Carrato A, et al. A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.J Clin Oncol. 2016;34 (suppl 4S; abstr 341).
17. Bekaii-Saab T, Mikhail S, Langleben A, et al. A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.J Clin Oncol.2016;34(suppl 4S; abstr 196).
18. Shahda S, El-Rayes BF, O’Neil BH, et al. A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).J Clin Oncol. 2016;34 (suppl 4S; abstr 284).
19. NewLink Genetics Corporation. Corporate Presentation. http://bit.ly/1VWVqRL. Created November 2015. Accessed April 28, 2016.
20. Le DT, Wang-Gillam A, Picozzi V Jr, et al. A phase 2, randomized trial of GVAX Pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Presented at: the ASCO Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, California. Abstract 177.